FDA Approves New Pancreatic Cancer Pill, Rasonque, for Advanced Treatment

The U.S. Food and Drug Administration has approved a new cancer treatment pill, Rasonque, manufactured by Revolution Medicines in California. This medication is designed as an inhibitor for the most common type of pancreatic cancer. It is taken once daily and targets multiple forms of the RAS protein, which plays a significant role in tumor growth.

The FDA described Rasonque as a “new treatment option for patients with advanced pancreatic cancer” and approved it over six months before their review deadline. According to acting FDA Commissioner Kyle Diamantas, this approval provides a crucial option for patients facing this traditionally difficult-to-treat cancer. He expressed pride in the FDA scientists whose efforts made this milestone possible through a fast and thorough review process.

The medication is intended for adults with metastatic pancreatic cancer that has not responded to previous treatments or cannot undergo certain combination drug therapies. Pancreatic adenocarcinoma is a particularly lethal form of cancer in the U.S., responsible for approximately 95% of pancreatic cancer cases annually.

Despite representing only 3.2% of total cancer diagnoses, the disease accounts for a high number of cancer deaths due to its late detection and rapid spread. Approval followed a randomized, open-label trial involving 500 patients with pre-treated metastatic disease, where those taking Rasonque had a median overall survival of 13.2 months, nearly twice the 6.7-month survival period of those receiving standard chemotherapy.

Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, stated, “This drug showed unprecedented results in an area of high unmet need.” The drug gained priority review, orphan drug status, and breakthrough therapy designation, further accelerating its market approval.

The FDA also used the National Priority Voucher pilot program to hasten access to this important public health treatment. Before official approval, a “safe to proceed” letter was issued in May, allowing an expanded access protocol for patients.

Reported side effects in clinical trials include rash, diarrhea, mouth sores, nausea, fatigue, vomiting, abdominal pain, edema, reduced appetite, and bleeding. Anna Berkenblit, M.D., of the Pancreatic Cancer Action Network, termed the approval “a significant advance,” suggesting that Rasonque may transform the treatment of pancreatic cancer by offering patients more time and potentially improved quality of life.